Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Anebulo Pharmaceuticals, Inc. ANEB
$2.33
-$0.01 (-0.21%)
На 18:04, 12 мая 2023
Ранг: 3
Ключевые показатели
-
Marketcap
58956360.00000000
-
week52high
7.00
-
week52low
1.77
-
Revenue
0
-
P/E TTM
-6
-
Beta
0.00000000
-
EPS
-0.37000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 февр 2023 г. в 13:00
Описание компании
Anebulo Pharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing and commercializing treatments for people suffering from acute cannabinoid intoxication and substance addiction. Its lead product candidate is ANEB-001, a small molecule cannabinoid receptor antagonist to treat cannabinoid intoxication and overdose. The company was incorporated in 2020 and is based in Lakeway, Texas.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Ladenburg Thalmann | Buy | 27 июл 2022 г. | |
| Benchmark | Buy | 25 мая 2021 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| Cundy Kenneth C | A | 35017 | 35017 | 09 дек 2022 г. |
| ALLEN SIMON | A | 70246 | 70246 | 09 дек 2022 г. |
| Calloway Nathaniel | A | 59149 | 59149 | 01 ноя 2022 г. |
| English Aron R. | A | 1703577 | 1703577 | 28 сент 2022 г. |
| English Aron R. | A | 5066290 | 1703577 | 28 сент 2022 г. |
| ALLEN SIMON | A | 77457 | 77457 | 27 июн 2022 г. |
| Cundy Kenneth C | A | 350169 | 350169 | 01 июн 2022 г. |
| Lin Kenneth | A | 30425 | 30425 | 21 апр 2022 г. |
| Lawler Joseph F. | A | 30425 | 30425 | 21 апр 2022 г. |
| Parschauer Karah Herdman | A | 30425 | 30425 | 21 апр 2022 г. |
Новостная лента
Anebulo: Interesting Drug For Cannabis Intoxication, But The Market Potential Remains Unclear
Seeking Alpha
27 янв 2023 г. в 15:49
Anebulo pharmaceutical is a US small-cap ($80M market cap) biotech company that is developing a phase 2 asset for cannabis-related intoxication. ANEB-001 targets a cannabinoid intoxication; we do not believe the market potential for "acute intoxication" to be as lucrative as the management suggests.
Anebulo's ANEB-001 Reduces Cannabis Intoxication In Healthy Participants
Benzinga
05 июл 2022 г. в 08:00
Anebulo Pharmaceuticals Inc (NASDAQ: ANEB) has announced topline data from Part A of an ongoing Phase 2 trial of ANEB-001 to treat acute cannabinoid intoxication (ACI). Part A was a 60-subject trial designed to evaluate the effectiveness of a single dose of ANEB-001 in healthy.
Anebulo Pharmaceuticals to Announce Topline Data for ANEB-001 from an Ongoing Phase 2 Clinical Trial for Acute Cannabinoid Intoxication on Tuesday July 5, 2022
Business Wire
23 июн 2022 г. в 16:00
AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid intoxication (ACI) and substance abuse disorder (the “Company” or “Anebulo”), anticipates releasing topline data from Part A of its ongoing Phase 2 study of ANEB-001 on July 5th. The results of the study, conducted in sixty healthy subjects challenged with delta-9-tetrahydrocannabinol, better known as THC,
Anebulo Pharmaceuticals Reports Q2 Financial Results, Plans To Develop Therapy For Acute Cannabinoid Intoxication
Benzinga
11 февр 2022 г. в 09:13
Anebulo Pharmaceuticals, Inc. ANEB announced financial results for the three months ended December 31, 2021 and recent updates. Q2 2022 Financial Highlights Operating expenses in the second quarter of fiscal 2022 were $1.1 million compared with $0.3 million in the same period in fiscal 2021.